AROMASIN Indication and Important Safety Information
Please scroll to see the Indication below.
Important Safety Information
AROMASIN should not be used in women who are premenopausal, are nursing or pregnant,
have a known hypersensitivity to the drug, or are taking estrogen-containing agents.
Dose modification is recommended for patients who are receiving certain medications,
including strong CYP 3A4 inducers such as rifampicin and phenytoin.
In patients with early breast cancer, elevations in bilirubin, alkaline phosphatase,
and creatinine were more common in those receiving AROMASIN than either tamoxifen
or placebo.
Reductions in bone mineral density over time are seen with use of AROMASIN.
In IES, incidence of adverse events (AEs; %) occurring in = 10% of patients in any
treatment group (AROMASIN vs tamoxifen) were hot flashes (21.2 vs 19.9), fatigue
(16.1 vs 14.7), arthralgia (14.6 vs 8.6), headache (13.1 vs 10.8), insomnia (12.4
vs 8.9), and increased sweating (11.8 vs 10.4). Discontinuation rates due to AEs
were similar between AROMASIN and tamoxifen (6.3% vs 5.1%).
In advanced breast cancer, only 3% of patients on AROMASIN discontinued treatment
due to adverse events. Most common adverse events were mild to moderate and included
hot flushes (13% vs 5%), nausea (9% vs 5%), fatigue (8% vs 10%), increased sweating
(4% vs 8%) and increased appetite (3% vs 6%) for AROMASIN and megestrol acetate,
respectively.
Indication
AROMASIN is indicated for adjuvant treatment of postmenopausal women with estrogen-receptor positive early breast cancer who have received 2 to 3 years of tamoxifen and are switched to AROMASIN for completion of a total of 5 consecutive years of adjuvant hormonal therapy.
AROMASIN is indicated for the treatment of advanced breast cancer in postmenopausal women whose disease has progressed following tamoxifen therapy.